BLOG / 🇺🇸 United States / broad market · · daily

US SEC Filings Daily Market Digest — November 06, 2026

Daily USA Market Intelligence

By Gunpowder Editorial ·

20 high priority 30 medium priority 50 total filings analysed

Executive Summary

Today's 50 SEC filings reveal a market defined by aggressive M&A consolidation, divergent earnings quality, and a clear split between companies executing turnarounds and those facing structural headwinds.

Deal activity dominates: Array Technologies' $1.8B profit-pool merger with Shoals, Varonis' $49.75/share take-private by Thoma Bravo, and multiple SPAC closings (Elroy Air, US Elemental) signal renewed risk appetite, while Beam Global's terminated ScoutDI acquisition highlights valuation discipline. Earnings trends are mixed: revenue growth is broad (Mattel +4.1%, Elanco +11%, AMN +13%, DraftKings +16.2%, Bowman +18%), but margin pressure is pervasive—Mattel's 9M operating income fell 5.2% on a 34.8% advertising surge, DraftKings' net loss widened to $469M on 68% S&M growth, and Tredegar's EBITDA collapsed 77%. Capital allocation is a bright spot: Plains All American raised its distribution 10% (~7% yield) and BILL repurchased $305M of stock, while Goldman Sachs BDC maintained its $0.32 dividend despite NAV erosion. Insider and activist activity is notable: Saba Capital accumulated 7.14% of BlackRock TCP and 13.48% of Ellsworth Growth, while X Financial's CEO launched a $6.03/ADS squeeze-out. Guidance changes skew positive (Elanco, Bloomin' Brands, Anika raised; Anika cut commercial growth), but the forward calendar is dense with binary events—Elroy Air's Nov 25 vote, Varonis' merger vote, and Vogenx's H2 2027 EMERGE readout.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 425 · 8-K · 13F · 10-Q · Schedule 13D · Schedule 13G

Tracking the trend? Catch up on the prior US SEC Filings Daily Market Digest digest from November 05, 2026.

Investment Signals (12)

  • Q3 revenue $1.265B (+11% YoY, 9% organic), net income swung to $18M from -$34M, Adj EPS $0.27 (+42%), FY26 revenue guidance raised to $5.155-$5.18B and Adj EPS to $1.17-$1.20, net leverage improved to 2.9x

  • Q3 Adjusted EBITDA +6% to $711M, Adj net income +12% to $373M, distribution raised 10% YoY to $0.4175/unit (~7% yield), closed ~$585M Silver Creek acquisition, expanded Permian JV by ~270,000 acres, reaffirmed FY26 EBITDA guidance $2.88B +/- $50M

  • ▲

    Q1 FY27 revenue $353.8M (+12.5% YoY), swung to net income $60.3M ($0.61 EPS) from -$3.0M, operating profit $51.2M vs -$20.7M, repurchased $304.9M of stock (shares down to 85.9M from 92.1M), R&D cut 37% and S&M cut 14.6%

  • Stock-for-stock merger creates combined company with >$20M annual cost savings, ~$1.8B US profit pool, pro forma 2026 net debt/EBITDA 2.6x falling below 2x in 2027, plans to redeem $161.3M preferred within 90 days and $156.3M over three years (reducing preferred >60%)

  • ▲

    Q3 revenue $717.3M (+13.0% YoY), net income $33.4M (+14.0%), diluted EPS $0.83 vs $0.76, 9M revenue +39.7% to $2,768.9M, cash surged to $256.0M from $34.0M at year-end 2025

  • Saba Capital/BlackRock TCP Capital (BULLISH)
    ▲

    Saba accumulated 5,986,934 shares (7.14% of outstanding) for ~$24.2M in open-market purchases from 10/14-11/5/2026 at $3.96-$4.37, including 698,126 shares on 11/5 at $4.10, signaling activist conviction in a beaten-down BDC

  • Saba Capital/Ellsworth Growth & Income Fund (BULLISH)
    ▲

    Saba raised stake to 1,821,810 shares (13.48%) for ~$15.25M, believes shares undervalued, may push for buybacks, tenders, liquidation, or conversion to open-end status, and may nominate board members

  • ▲

    FY26 diluted EPS guidance raised to $1.06-$1.11 from $0.85-$0.95, adjusted EPS raised to $0.97-$1.02 from $0.90-$1.00, Q3 revenue +1.7% to $944.3M helped by $13.2M gift card breakage, GAAP operating margin swung to 2.0% from (3.9)%

  • Q3 revenue $30.6M (+10% YoY), gross margin improved to 62% from 56%, raised low end of 2026 revenue growth guidance to 6%-10% and adjusted EBITDA margin guidance to 15%-17%

  • EVERTEC ↓ (BULLISH)
    ▲

    Amended credit agreement reprices ~$388M Term Loan A 25 bps lower and extends maturity up to five years; revolver upsized from $200M to $300M and repriced 25 bps lower, lowering borrowing costs

  • ▲

    Q2 FY27 net revenue $81.4M (+22% YoY), international cannabis revenue surged 141% to $12.3M on Germany/Poland medical sales, adjusted EBITDA loss narrowed 6% to $2.9M, free cash outflow improved to $15.5M from $19.2M

  • Vogenx ↓ (BULLISH)
    ▲

    Post-IPO cash $82.1M (from $601K), funded by ~$84.4M net IPO proceeds, Phase 2b EMERGE study of mizagliflozin initiated Oct 2026 with topline data expected H2 2027, Phase 2 gastroparesis study planned H1 2027

Risk Flags (10)

  • DraftKings↓ [HIGH RISK]
    ▼

    Q3 net loss widened to $468.7M from $256.8M as sales & marketing surged 68.1% to $605.7M, operating loss deepened to $493.1M, 9M operating cash flow collapsed to $63.0M from $342.4M, stockholders' equity fell to $179.6M from $631.5M

  • ▼

    10-Q/A restated H1 2026 with $2.7B impairment of cable franchise rights, net loss $2.45B vs $171.9M, revenue -4.9% YoY to $4.09B, total debt ~$26.6B, stockholders' deficiency widened to $(4.35B)

  • Tredegar↓ [HIGH RISK]
    ▼

    Q3 net loss $(2.8)M vs $7.1M income, consolidated EBITDA from ongoing ops collapsed 77% to $4.1M from $18.1M, Aluminum Extrusions EBITDA -84.9% to $2.5M, FIFO timing mismatch swung to $2.8M charge from $4.3M benefit

  • Goldman Sachs BDC↓ [HIGH RISK]
    ▼

    Q3 EPS $(0.04) vs NII $0.32, net realized/unrealized losses widened to $(39.3)M from $(18.6)M, total investment income -10.4% to $75.0M, NAV/share -3.0% to $11.70, non-accruals rose to 4.2% from 2.9% at fair value (7.3% from 5.0% at cost), five new non-accrual placements

  • ▼

    Q3 revenue -14.5% to $56.6M, total expenses surged 82.8% to $76.7M (employee comp $70.5M vs $5.7M), operating loss $20.1M vs $24.2M income, net loss attributable to PS Inc. $19.9M vs $155.5M income, 9M net loss $210.2M vs $198.9M income

  • NextCure↓ [HIGH RISK]
    ▼

    S-4/A shows existing holders diluted to ~0.99% of combined company post-merger with Avere, will become a shell company disposing of legacy IP, accumulated deficit $460.7M, ineligible issuer for 3 years, Rule 144 restrictions until 1 year after Form 10

  • Bowman Consulting↓ [HIGH RISK]
    ▼

    Q3 swung to net loss $(1.988)M from $6.618M income, diluted EPS -$0.12 vs $0.37, 9M net loss $(3.195)M vs $10.883M income, cash fell to $5.247M from $11.066M, revolver borrowings rose to $139.0M from $95.4M

  • PSQ Holdings↓ [HIGH RISK]
    ▼

    9M cost of revenue surged 222.9% to $10.10M vs $3.13M, outpacing revenue growth and compressing gross margin, cash plunged to $3.84M from $14.64M, stockholders' equity only $1.70M vs $13.44M

  • ▼

    Q3 revenue -3.9% YoY to $48.253M, 9M revenue -6.2% to $140.827M, net loss $12.566M, cash declined to $7.760M from $10.708M, inventories rose 17.4% to $42.304M while receivables dropped 28.3%, stockholders' equity fell to $61.6M from $87.3M

  • Anika Therapeutics↓ [HIGH RISK]
    ▼

    FDA notified in October that Hyalofast PMA application is not approvable based on clinical data, 2026 Commercial Channel growth guidance cut to 9%-13% from 12%-18%, 2027 total revenue growth guided flat to 5% with OEM flat to modestly lower

Opportunities (10)

  • ◆

    Take-private at $49.75 cash per share, Board unanimously recommends approval, merger agreement dated Oct 15, 2026; arb spread opportunity pending shareholder vote (abstentions count as against, so turnout is critical)

  • Elroy Air/Inflection Point Acquisition Corp VII (OPPORTUNITY)
    ◆

    SEC declared S-4 effective, shareholder vote set for Nov 25, 2026, closing expected Dec 2026 under ticker 'ELRY'; ~$175M total financing commitments including $75M pre-PIPE already funded and $100M PIPE at closing; redemption deadline Nov 23

  • US Elemental/Constellation Acquisition Corp I (OPPORTUNITY)
    ◆

    SEC declared S-4 effective for McDermitt lithium assets listing on Nasdaq under 'ULIT' with Jindalee retaining 80%+ ownership, PIPE $20M-$30M including $4.0M binding sponsor affiliate commitment, $14M minimum cash condition, targeted Q4 2026 close

  • X Financial↓ (OPPORTUNITY)
    ◆

    Chairman/CEO Yue Tang's Mangrove Coast proposed buyout at $1.005/ordinary share ($6.03/ADS), Mangrove already holds ~93.45% voting power; special committee to be formed, potential minority squeeze-out premium

  • Stockholders approved all merger proposals including share issuance, reverse split (1-for-2 to 1-for-10), and renaming to Remix Therapeutics; 2026 EIP (5.77M shares) and ESPP (440K shares) approved, though ~25% voted against equity plans—watch for governance friction

  • Alphabet 13F (OPPORTUNITY)
    ◆

    Discloses $88.3B portfolio with SpaceX Class A at $55.5B and Planet Labs at $35.2B (~99% of value), plus Arm Holdings $19.6B; provides rare mark-to-market visibility into private space/tech holdings

  • SABESP (OPPORTUNITY)
    ◆

    3Q26 adjusted EBITDA +13.8% to R$3,648M (61% margin), adjusted net revenue from core services +9.0% on +7.7% price and +2.1% volume, capex +13.8% to R$4,528M; reported net income -35.7% due to prior-year R$1.5B precatórios gain, creating a clean comparison opportunity

  • Committed 3.5M tons of 2027 met coal to domestic customers at average $135.48/ton, 2027 guidance 14.3-15.7M total tons, Q3 realization $121.09/ton vs $118.71 QoQ; cost pressures ($106.93/ton) and DTA stacker reclaimer damage are key swing factors

  • Docebo↓ (OPPORTUNITY)
    ◆

    Two acquisitions totaling $67.9M ($60.8M + $7.1M) added $36.9M goodwill, $15.9M customer relationships, $8.4M technology; funded largely by $54.3M cash—watch for revenue synergies and integration execution

  • Mattel↓ (OPPORTUNITY)
    ◆

    Q3 net sales +4.1% to $1,806.7M, gross profit +14.0% to $989.6M, operating income +25.4% to $476.3M, diluted EPS +39.8% to $1.23; 9M net income $396.4M includes $147.9M gain on remeasurement of previously held equity interest—core toy demand is strong despite cash burn

Sector Themes (6)

  • M&A and Take-Private Wave
    ◆

    At least 8 filings involve mergers, acquisitions, or take-privates (Array/Shoals, Varonis/Thoma Bravo, Passage BIO/Remix, Elroy Air/IPXG, US Elemental/Constellation, NextCure/Avere, Docebo acquisitions, Beam Global termination), signaling robust deal appetite and a supportive financing environment despite elevated rates

  • Margin Compression Despite Revenue Growth
    ◆

    A recurring pattern across consumer, tech, and industrial names—Mattel 9M operating income -5.2% on +5.9% sales (advertising +34.8%), DraftKings net loss widened on +16.2% revenue (S&M +68.1%), Bowman net loss on +18% revenue, Tredegar EBITDA -77% on +9.1% Aluminum Extrusions sales—suggesting cost inflation and growth investment are squeezing profitability broadly

  • BDC and Credit Stress
    ◆

    Goldman Sachs BDC non-accruals rose to 4.2% from 2.9% at fair value (7.3% from 5.0% at cost) with five new non-accrual placements, NAV -3.0%, and EPS negative despite $0.32 NII; Saba's activist accumulation in BlackRock TCP (7.14%) and Ellsworth (13.48%) suggests deep-value opportunities in closed-end/BDC structures

  • Cannabis Sector Divergence
    ◆

    Canopy Growth revenue +22% YoY with international +141% and adjusted EBITDA loss narrowing to $2.9M, but gross margin contracted to 29% from 33% on lower VAC reimbursement and net loss widened by $35.7M on Canopy USA fair value charges—growth vs. profitability remains the central tension

  • SPAC and De-SPAC Activity Reviving
    ◆

    Elroy Air ($175M commitments, Nov 25 vote), US Elemental (SEC effective, Q4 2026 close), and Passage BIO/Remix approvals indicate the SPAC pipeline is thawing, though non-binding LOIs (Elroy) and minimum cash conditions ($14M for US Elemental) remain execution risks

  • Activist and Insider Conviction
    ◆

    Saba Capital's dual campaigns (BlackRock TCP 7.14%, Ellsworth 13.48%) and X Financial CEO's buyout proposal at $6.03/ADS demonstrate insiders and activists see value in beaten-down financials and small caps; conversely, no major insider selling was disclosed today, a mildly positive signal

Watch List (8)

  • Elroy Air/IPXG
    👁

    Shareholder vote Nov 25, 2026; redemption deadline Nov 23 at 5:00 p.m. ET; watch redemption levels vs. $100M PIPE condition and non-binding LOI conversion to firm orders

  • Merger vote date TBD (proxy preliminary); $49.75 cash per share; abstentions count as votes against—monitor turnout and any competing bids

  • US Elemental/Constellation Acquisition Corp I
    👁

    Q4 2026 target close; $14M minimum cash condition and $20M-$30M PIPE including $4.0M binding commitment; watch for Nasdaq listing approval and any PIPE shortfall

  • Special committee formation and independent advisors; CEO Tang recused; watch for definitive offer or competing proposals given 93.45% voting concentration

  • 👁

    Phase 2b EMERGE topline data expected H2 2027; Phase 2 gastroparesis study initiation H1 2027; cash runway from $82.1M post-IPO

  • Hyalofast PMA not approvable—watch for FDA feedback, potential resubmission strategy, and 2027 revenue growth of flat to 5%

  • Q3 FY27 earnings (quarter ending Dec 31, 2026) to assess VAC reimbursement impact, international momentum, and path to adjusted EBITDA breakeven

  • Saba Capital/BlackRock TCP & Ellsworth
    👁

    Watch for 13D amendments, board nomination announcements, and any issuer response (buybacks, tenders, strategic reviews)

Filing Analyses (50)
Array Technologies, Inc. 425 positive materiality 9/10

05-11-2026

Array Technologies and Shoals Technologies Group announced a stock-for-stock merger in which Array is the legal acquirer and surviving entity, with each Shoals share exchanged for 1.6931 Array shares; Shoals shareholders will own approximately 65% of the combined company and Array shareholders 35%. The companies expect more than $20 million in annual cost savings from eliminating duplicate public company costs and cite a ~$1.8 billion annual US profit pool, but only 20% of solar projects currently use products from both companies, and the deal remains subject to shareholder and regulatory approvals with closing targeted for Q1 2027. The combined company plans to redeem $161.3 million of preferred stock within 90 days of closing and an additional $156.3 million over three years, reducing preferred outstanding by over 60%, while carrying pro forma 2026 net debt to EBITDA of 2.6x (below 2x expected in 2027).

  • · Transaction structured to avoid refinancing Array's existing debt, preserving attractive financing and reducing execution risk
  • · All shares exchanged for Array common stock at closing; Array share price will reflect combined business thereafter
  • · New corporate name and ticker symbol to be announced in coming months
  • · Registration statement and joint proxy statement/prospectus expected to be filed with SEC in coming weeks
  • · Combined company will supply essentially all key sBOS and EBOS components for utility-scale solar projects
  • · Potential product innovations include tracker torque tubes with integrated attachment points for Shoals BLA, integrated wire management, pre-engineered kits, and digital design tools
  • · Deal requires majority approval of both Array and Shoals shareholders plus regulatory approvals
Constellation Acquisition Corp I 425 mixed materiality 7/10

05-11-2026

The SEC declared effective US Elemental Inc.'s Form S-4 registration statement for its proposed business combination with Constellation Acquisition Corp I, a key procedural step toward listing McDermitt lithium assets on Nasdaq under ticker "ULIT" with Jindalee expected to retain 80%+ ownership. The deal contemplates a PIPE financing of approximately $20M-$30M, including a binding $4.0M commitment from a Constellation sponsor affiliate ($1.5M already funded, $2.5M at closing), but remains subject to a $14M minimum cash condition, Constellation shareholder approval, and Nasdaq listing approval. Completion is targeted for Q4 2026, though the filing cautions there can be no assurance conditions will be met or the deal completed on schedule.

  • · SEC effectiveness is a procedural step and does not represent SEC approval of the Business Combination
  • · Jindalee shareholder approval for the Business Combination was obtained in June 2026
  • · SEC review process began with initial filing in June 2026
  • · PIPE term sheets from several US funds are non-binding; target may be met subject to further negotiation and definitive agreements
  • · HiTech Minerals owns 100% of the McDermitt Lithium Project in southeast Oregon
  • · Constellation sponsors entered a support agreement to vote their shares in favor of the Business Combination
  • · Constellation trades OTCPK: CSTAF; Jindalee trades ASX: JLL, OTCQX: JNDAF
  • · Remaining closing conditions include regulatory approvals and absence of material adverse change events
X Financial 6-K neutral materiality 8/10

06-11-2026

On November 6, 2026, X Financial's (NYSE: XYF) board received a preliminary non-binding proposal from Mangrove Coast Investment Limited, affiliated with Chairman and CEO Yue (Justin) Tang, to acquire all outstanding ordinary shares not beneficially owned by Mangrove at US$1.005 per ordinary share, or US$6.03 per ADS (each ADS representing six Class A ordinary shares). Mangrove already holds approximately 93.45% of total voting power, leaving a small public float subject to the buyout; the Board has not yet evaluated the proposal, intends to form an independent special committee with independent financial and legal advisors, and Tang will recuse himself. No definitive offer or agreement is assured.

  • · Proposal letter is dated November 6, 2026 and attached as Exhibit 99.1
  • · Mangrove is acquiring only shares it does not already beneficially own, implying a minority squeeze-out of the public float
  • · Mr. Tang is affiliated with Mangrove and will recuse himself from Board deliberations and decisions on the proposal
  • · Board cautions it has just received the letter and has not had an opportunity to review or evaluate the proposal
  • · No assurance that a definitive offer will be made, an agreement executed, or the transaction approved or consummated
  • · Company files annual reports under Form 20-F; SEC commission file number 001-38652
Passage BIO, Inc. 8-K mixed materiality 8/10

06-11-2026

Passage Bio stockholders approved all proposals at the November 5, 2026 Special Meeting related to the merger with Remix Therapeutics, including issuance of Passage Bio shares to Remix securityholders (change of control under Nasdaq Rules 5635(a)/(b)), a reverse stock split of 1-for-2 to 1-for-10, and renaming the company to 'Remix Therapeutics, Inc.' The 2026 Equity Incentive Plan (5,772,500 shares reserved) and 2026 ESPP (440,000 shares) were also approved. However, support was notably weaker on equity plan proposals — Proposal 5 (2026 EIP) drew 458,604 votes against (~25% of votes cast) and Proposal 6 (ESPP) passed with only 1,383,770 for versus 458,604 against, while charter governance changes (4D, 4H) also saw meaningful opposition (~355,000-363,000 against).

  • · Proposal 1 (share issuance to Remix holders): 1,806,227 for, 36,404 against, 553 abstaining, 475,637 broker non-votes
  • · Proposal 2 (Reverse Stock Split 1-for-2 to 1-for-10): 2,202,453 for, 113,608 against, 2,760 abstaining
  • · Proposal 3 (rename to Remix Therapeutics, Inc.): 1,809,243 for, 33,290 against, 651 abstaining
  • · Proposal 4D (supermajority bylaw requirement): 1,479,152 for vs 363,438 against — largest opposition among charter proposals
  • · Proposal 4H (supermajority for enumerated charter provisions): 1,485,412 for vs 355,992 against
  • · Proposal 6 (2026 ESPP): 1,383,770 for vs 458,604 against
  • · Merger Agreement dated September 2, 2026, amended October 5, 2026
  • · Proxy Statement/Prospectus filed October 9, 2026; Record Date September 30, 2026
  • · 2026 Plan annual increase runs January 1, 2027 through January 1, 2036
  • · Passage Bio is a remote-only company with no headquarters; stockholder communications directed to P.O. Box 7, Hopewell, New Jersey 08525
VARONIS SYSTEMS INC PREM14A neutral materiality 9/10

06-11-2026

Varonis Systems filed a preliminary proxy statement (PREM14A) for a special meeting where stockholders will vote on its acquisition by Proofpoint, Inc. (a Thoma Bravo affiliate) via merger sub Vail Merger Sub, Inc., under a Merger Agreement dated October 15, 2026. Stockholders would receive $49.75 in cash per share, with the Board unanimously recommending approval of the merger, the advisory compensation proposal, and the adjournment proposal. The deal requires approval by a majority of the voting power of outstanding shares, and abstentions/non-votes effectively count as votes against.

  • · Merger Agreement dated October 15, 2026 among Varonis, Proofpoint, Inc. (Parent) and Vail Merger Sub, Inc.
  • · Parent and Merger Sub are affiliated with private equity firm Thoma Bravo, L.P.
  • · Upon completion, Varonis becomes the surviving corporation and a wholly-owned subsidiary of Parent
  • · Board formed a Transaction Committee to review and negotiate the transaction; Board acted on its unanimous recommendation
  • · Failure to vote (assuming quorum) has the same effect as a vote AGAINST the Merger Agreement Proposal
  • · Stockholders may seek appraisal rights under Section 262 of the Delaware General Corporation Law
  • · Proxy solicitor is Okapi Partners LLC (New York); toll-free stockholder line (888) 785-6709
  • · Risk Factors discussion begins on page 9 of the Company's Annual Report on Form 10-K for year ended December 31, 2025
  • · Special Meeting to be held virtually; record date and meeting date left as placeholders [•]
  • · Company incorporated in Delaware; fiscal year end December 31; SEC file number 001-36324
MITSUBISHI UFJ FINANCIAL GROUP INC 13F-HR neutral materiality 4/10

06-11-2026

Mitsubishi UFJ Financial Group filed its Q3 2026 (period ended September 30, 2026) 13F-HR combination report disclosing institutional holdings across its subsidiaries. The portfolio is overwhelmingly concentrated in a single position: 375,330,252 shares of Morgan Stanley valued at $70,592,113,796, dwarfing all other disclosed holdings. The remaining disclosed positions are small by comparison — Figure Technology Solutions ($66,859,615), Securitize Corp ($9,492,342), and Teamshares Inc ($8,717,942) — highlighting extreme single-name concentration risk in the reported book.

  • · Report is a 13F combination report covering 10 reporting manager subsidiaries under SEC file 028-13582
  • · Morgan Stanley position carries sole voting authority over all 375,330,252 shares (0 shared, 0 none)
  • · Figure Technology Solutions, Securitize, and Teamshares positions are all marked DFND (defined) with sole discretion
  • · MUFG states it does not directly exercise investment discretion except positions included in this form
  • · Filing signed by Hidetoshi Fuwa in Tokyo on November 5, 2026; period of report September 30, 2026
  • · Filer SIC classification: Commercial Banks, NEC [6029]; fiscal year end March 31
Andar Capital Management HK Ltd 13F-HR neutral materiality 4/10

06-11-2026

Andar Capital Management HK Ltd filed its Q3 2026 13F-HR disclosing a 13-position US equity portfolio concentrated in semiconductor and electronic-component names, with total reported holdings of approximately $188.3 million as of September 30, 2026. The largest positions were Micron Technology ($27.69M), Semtech ($26.04M), Vicor ($31.21M) and Onto Innovation ($20.32M), while smaller stakes included Diodes ($7.74M), Vishay Intertechnology ($4.56M) and Vishay Precision ($3.64M). The filing is a new-holdings snapshot with no prior-period comparison disclosed, so period-over-period changes cannot be assessed.

  • · All 13 positions are held in sole voting authority with zero shared or discretionary-other voting, indicating full control over the disclosed stakes.
  • · Portfolio is heavily weighted toward semiconductors and electronic components, with the top four positions (Vicor, Micron, Semtech, Onto Innovation) accounting for roughly $105.3M, or about 56% of total holdings.
  • · Filing is a 13F-HR for the period ended 09-30-2026, filed 11-06-2026; no prior-quarter holdings are included for comparison.
  • · Filer is a Hong Kong-based entity (SEC file number 028-20623) with CRD/CIK 0001805591.
Columbus Circle Capital Corp II 425 mixed materiality 8/10

06-11-2026

Elroy Air and Inflection Point Acquisition Corp. VII (f/k/a Columbus Circle Capital Corp II, Nasdaq: IPXG) announced the SEC declared effective their Form S-4 registration statement for their proposed business combination, with a shareholder vote set for November 25, 2026 and closing expected in December 2026 under ticker 'ELRY'. Elroy Air has secured approximately $175 million in total financing commitments, including $75 million of pre-PIPE financing already funded and a $100 million PIPE expected at closing. However, the company's demand pipeline consists of non-binding LOIs, MOUs and uncommitted reservations, and its up-to $46 million U.S. Army contract is subject to option exercise and Congressional appropriations, leaving revenue realization uncertain.

  • · Extraordinary General Meeting set for 10:00 a.m. ET on November 25, 2026 at White & Case LLP, 1221 Avenue of the Americas, New York, with virtual webcast
  • · Record date for voting: close of business October 30, 2026
  • · Redemption deadline for public shareholders: 5:00 p.m. ET on November 23, 2026
  • · Combined company expected to trade on Nasdaq under ticker 'ELRY', subject to Nasdaq approval
  • · Kratos Defense & Security Solutions is Chaparral's exclusive U.S. manufacturer, producing at its Sacramento, California facility with first production aircraft planned for late 2026
  • · Elroy Air completed first autonomous and uncrewed flights under the FAA/DOT eIPP in partnership with Bristow Group
  • · Elroy Air facilities located in Byron, California
  • · Demand pipeline consists of non-binding LOIs, MOUs and uncommitted early delivery reservations that may not convert to sales
  • · U.S. Army contract is subject to government termination for convenience and future funding contingent on option exercise and annual budget approvals
  • · Chaparral designed to operate with no runways or charging infrastructure via hybrid-electric powertrain
IvyRock Asset Management (HK) Ltd 13F-HR neutral materiality 4/10

06-11-2026

IvyRock Asset Management (HK) Ltd filed its Q3 2026 13F-HR disclosing 20 equity positions as of September 30, 2026. The portfolio is heavily concentrated in PDD Holdings ($90.6M, 1,162,749 ADS) and iShares Bitcoin Trust ($29.3M, 619,400 shares), followed by Alibaba ($25.6M) and Legend Biotech ($15.3M). The filing shows no period-over-period comparison data, so quarter-over-quarter position changes cannot be assessed from this disclosure alone.

  • · Filing is a 13F-Holdings Report for the period ending September 30, 2026, filed November 6, 2026 (SEC File No. 028-20571)
  • · All 20 positions are held in sole voting authority; no shared or discretionary split reported
  • · Legend Biotech shows 155,600 shares of put/call or other option exposure in the 'putCall' column
  • · PDD Holdings shows 234,949 shares of option exposure in the 'putCall' column
  • · KE Holdings shows 8,000 shares of option exposure in the 'putCall' column
  • · Portfolio has a strong China/Asia tech tilt (PDD, Alibaba, KE Holdings, HUYA, JOYY, Legend Biotech, ATRenew) alongside crypto (iShares Bitcoin Trust) and precious-metals ETFs
  • · No period-over-period holdings comparison is included, so QoQ position changes cannot be determined from this filing
Docebo Inc. 6-K mixed materiality 6/10

06-11-2026

Docebo Inc. filed a 6-K containing notes to its unaudited condensed consolidated interim financial statements for the period ended September 30, 2026, disclosing two business acquisitions with total purchase consideration of $60.8M and $7.1M respectively. The larger deal added $36.9M of goodwill, $15.9M of customer relationships and $5.6M of technology, funded largely by $54.3M in cash plus holdback and contingent consideration. However, trade receivables declined to $44.5M from $45.5M at year-end 2025, and intangible amortization of $4.5M weighed on carrying values, while lease and property balances showed mixed movements.

  • · Larger acquisition fair value of net assets acquired was $60.8M, including $6.5M current assets and $6.5M total liabilities.
  • · Smaller acquisition fair value of net assets acquired was $7.1M, including $3.1M goodwill and $2.9M technology.
  • · Intangibles added through business combinations totaled $26.5M (customer relationships $15.9M, technology $8.4M, trademarks $2.2M).
  • · Right-of-use asset net balance rose to $5.2M from $2.4M at December 31, 2025.
  • · Lease liability balance was $5.3M at September 30, 2026, of which $1.8M current and $3.5M non-current.
  • · Property and equipment additions were $0.5M for the period, with depreciation of $0.6M.
  • · Interest receivable fell to nil from $39 thousand at December 31, 2025.
Goldman Sachs BDC, Inc. 8-K mixed materiality 7/10

06-11-2026

Goldman Sachs BDC reported Q3 2026 net investment income per share of $0.32 (annualized NII yield on book value of 10.9%), but earnings per share were $(0.04) as net realized and unrealized losses widened to $(39.3) million from $(18.6) million in Q2 2026. Total investment income fell 10.4% to $75.0 million from $83.7 million on a smaller portfolio and non-accrual placements, while NAV per share declined 3.0% to $11.70 from $12.06 and non-accrual investments rose to 4.2% of the portfolio at fair value from 2.9%. The Board declared a Q4 2026 base dividend of $0.32 per share, and net debt-to-equity improved to 1.21x from 1.35x.

  • · Earnings per share for Q3 2026 was $(0.04) versus net investment income per share of $0.32.
  • · Non-accrual investments rose to 4.2% of the portfolio at fair value from 2.9%, and to 7.3% from 5.0% at amortized cost.
  • · Chase Industries (Senneca Holdings) was restored to accrual status, while Center for Sight, HungerRush, ATX Networks and Streamland Media were placed on non-accrual.
  • · Weighted average leverage (net debt/EBITDA) rose to 6.3x from 5.9x at December 31, 2025, while interest coverage fell to 1.9x from 2.0x.
  • · Weighted average yield at amortized cost declined to 9.7% from 9.9% at December 31, 2025.
  • · Net expenses decreased $1.9 million to $38.8 million, driven by lower interest expense and management fees.
  • · The Company repurchased approximately 1.5 million shares for $15.0 million during Q3 2026 under its $75.0 million 10b5-1 plan.
  • · Q4 2026 base dividend of $0.32 per share is payable on or about January 27, 2027 to holders of record as of December 31, 2026.
  • · Earnings conference call scheduled for Friday, November 6, 2026 at 9:00 am Eastern Time.
INVESCO DB AGRICULTURE FUND 10-Q mixed materiality 6/10

06-11-2026

Invesco DB Agriculture Fund (DBA) reported Q3 2026 net income of $59,019,905, up sharply from $16,878,645 in Q3 2025, driven by a $61,855,399 unrealized gain on commodity futures versus $27,492,031 a year earlier. However, net realized losses on commodity futures widened to $(11,955,267) from $(17,349,774) prior-year quarter, and interest income fell to $802,590 from $1,523,109. For the nine months, net income rose to $79,169,733 from $441,670, but net realized futures losses of $(4,204,408) replaced prior-year gains of $32,528,363, while total expenses rose to $7,498,563 from $5,559,457.

  • · Unrealized appreciation on commodity futures totaled $49,405,156 at Sept 30, 2026, with losses in Feeder Cattle (-$4,470,866), Lean Hogs Feb-2027 (-$3,872,218), Lean Hogs Dec-2026 (-$7,258,896) and Coffee (-$3,850,856) offsetting gains led by Soybean (+$17,814,182) and Cocoa (+$9,323,474)
  • · Management fees rose to $7,094,958 for nine months 2026 from $5,217,196, with fee waivers of $726,342
  • · Shares outstanding grew 65.4% to 46,800,000 from 28,300,000 at year-end 2025, reflecting $1,240,200,542 of purchases against $724,612,578 of redemptions
  • · Q3 2026 share transactions were net positive 3,600,000 shares ($105,456,279), versus net redemptions of 550,000 shares in Q3 2025
  • · Dividends from affiliates rose to $27,085,345 for nine months 2026 from $17,796,954
  • · Variation margin payable on commodity futures was $5,209,368 at Sept 30, 2026 versus zero at Dec 31, 2025
  • · Market value per share of $28.14 was essentially at NAV of $28.15
EVERTEC, Inc. 8-K positive materiality 6/10

06-11-2026

EVERTEC entered an amended and restated credit agreement extending its approximately $388 million Term Loan A for up to five years and repricing it 25 basis points lower, while the revolving credit facility was also extended, repriced 25 basis points lower, and upsized from $200 million to $300 million. The transaction lowers borrowing costs and extends maturities, though it increases total revolver capacity and potential leverage. Truist Bank serves as administrative and collateral agent, with six joint lead arrangers.

  • · Term Loan A maturity extended for up to five years
  • · Revolving credit facility also extended and repriced 25 basis points lower
  • · Truist Bank acted as administrative agent and collateral agent
  • · Six banks acted as joint lead arrangers: Truist Securities, Banco Popular de Puerto Rico, Citizens Bank, FirstBank Puerto Rico, Fifth Third Bank, and The Huntington National Bank
  • · EVERTEC operates across 29 countries and territories
  • · Forward-looking statements reference 10-K for fiscal year ended December 31, 2025 filed March 2, 2026
Vogenx, Inc. 8-K mixed materiality 7/10

06-11-2026

Vogenx reported Q3 2026 financial results following its August 2026 IPO, with cash, cash equivalents, and marketable securities rising to $82.1 million as of September 30, 2026 from $601 thousand at December 31, 2025, funded by ~$84.4 million in net IPO proceeds. However, net loss widened sharply to $4.9 million (or $(0.47) per share) from $284 thousand (or $(0.05) per share) a year earlier, driven by a $3.4 million change in warrant liability and higher operating expenses, while R&D rose to $1.1 million from $125 thousand and G&A to $704 thousand from $178 thousand. The company initiated the Phase 2b EMERGE study of mizagliflozin in PBH in October 2026, with topline data expected in H2 2027.

  • · IPO priced at $13.00 per share for 7,187,500 shares, including full exercise of underwriter's 937,500-share option
  • · EMERGE Phase 2b study evaluates mizagliflozin 5 mg and 10 mg for 28 days in ~36 adults with PBH, with topline results expected H2 2027
  • · Phase 2 study of mizagliflozin for gastroparesis planned to initiate in H1 2027
  • · Nine-month 2026 net loss was $5.8 million vs $936 thousand in the prior year period
  • · Nine-month 2026 R&D was $1.5 million vs $431 thousand; G&A was $1.1 million vs $555 thousand
  • · Weighted average diluted shares rose to 10,404,831 in Q3 2026 from 5,451,873 in Q3 2025
  • · Total stockholders' equity was $82.0 million at September 30, 2026 vs a deficit of $(919,235) at December 31, 2025
  • · Company disclosed material weaknesses in internal control over financial reporting
  • · Convertible promissory notes payable (related party) of $816,300 at December 31, 2025 were eliminated by September 30, 2026
Castellum, Inc. 8-K mixed materiality 6/10

06-11-2026

Castellum reported Q3 2026 revenue of $14.7 million, up just 0.7% YoY from $14.6 million but up 5.8% QoQ from $13.9 million, while 9M 2026 revenue grew 6% to $42.9 million from $40.3 million. However, gross profit fell to $5.3 million (36% margin) from $5.5 million (38%) in Q3 2025, Adjusted EBITDA dropped to ~$0.6 million from $1.1 million YoY, and the company swung to a net loss of $(0.5) million from net income of $0.4 million a year ago. Total backlog declined to $254.5 million from $271.7 million at June 30, 2026, though the qualified opportunity pipeline surged to ~$1.662 billion from $953.5 million, and the balance sheet remains debt-free with $15.7 million cash and $24.5 million in cash plus receivables.

  • · Q3 2026 gross margin compressed to 36% from 38% YoY, driven by higher mix of lower-margin subcontractor work
  • · Total backlog of $254.5 million consisted of only $18.2 million funded and $236.3 million unfunded
  • · Backlog reporting was refined to include priced contract options previously reported separately within unfunded backlog
  • · Company expects to recognize ~25% of remaining performance obligations within 12 months and ~51% within 24 months
  • · Operating cash flow turned positive at $1.1 million in 9M 2026 versus $1.3 million used in 9M 2025
  • · Combined cash and accounts receivable increased by an average of $0.5 million per quarter in 2026
  • · Derivative liability fell to $10,000 from $262,000 at December 31, 2025; related-party notes payable of $400,000 were eliminated
  • · Goodwill held flat at $10,676,834; intangible assets declined to $4,457,964 from $5,371,602
  • · Company expects record full-year 2026 revenue
  • · Management sees M&A as principal path to accelerate growth over the next 6 to 12 months
NextCure, Inc. S-4/A negative materiality 8/10

06-11-2026

NextCure filed an amended S-4/A on November 5, 2026 for its proposed Merger with Avere, under which NextCure will dispose of its legacy technology and IP and become a shell company upon closing. Post-merger ownership on a fully diluted basis is highly dilutive to existing NextCure holders: NextCure securityholders are expected to own only ~0.99% of the combined company, while former Avere holders (excluding the pre-closing financing) own ~39.69% and Avere pre-closing financing investors own ~59.32%. NextCure remains deeply loss-making, with net losses of $24.7M for the six months ended June 30, 2026 (improved from $37.8M in 2025) but $55.8M for FY2025 versus $55.7M in FY2024 (essentially flat), and an accumulated deficit of $460.7M as of June 30, 2026.

  • · NextCure will become a shell company upon consummation of the Merger and will dispose of its legacy technology and intellectual property, contingent on stockholder approval of the Required Proposals.
  • · Combined company will be an 'ineligible issuer' for three years post-closing, cannot use Form S-3 until 12 full calendar months after closing, and must wait at least 60 calendar days to file a Form S-8.
  • · Rule 144(i)(2) will limit public resale of Rule 145(c) securities and other restricted/control securities until one year after Form 10 information is filed.
  • · NextCure directors and officers have support agreements to vote in favor of the Required Proposals; Avere officers, directors and certain stockholders holding ~40% of Avere capital stock have similar support and lock-up agreements.
  • · The Merger Agreement includes termination fees and non-solicitation provisions that may discourage competing proposals.
  • · NextCure was founded in 2015, has no products approved for commercial sale, and has never generated revenue from product sales.
  • · Directors and executive officers of both companies have interests in the Merger (option acceleration, cash payments for in-the-money options, severance) that may differ from stockholders' interests.
Gagnon Advisors, LLC 13F-HR neutral materiality 3/10

06-11-2026

Gagnon Advisors, LLC filed its Q3 2026 13F-HR disclosing 24 equity positions with an aggregate reported value of approximately $182.06M as of September 30, 2026. The portfolio is heavily concentrated in small/mid-cap healthcare and technology names, led by CareDx ($18.65M), Enterprise Products Partners ($12.10M), GeneDx ($11.79M), Five9 ($11.44M) and Hinge Health ($11.02M). The filing reflects a snapshot of holdings only, with no prior-period comparison disclosed, so quarter-over-quarter position changes cannot be assessed from this document.

  • · All 24 positions are held with sole voting authority (0 shared/0 other), indicating no reported shared or discretionary split.
  • · Portfolio is concentrated in healthcare/biotech and small-cap technology names, with several micro-cap positions such as Beyond Meat ($107,066) and CNFinance ($471,976).
  • · Largest share-count positions include Kaltura (2,487,034 shares), Treace Medical (1,534,034 shares) and OraSure (1,285,032 shares).
  • · Filing signed by Lisa Ferrante, Chief Compliance Officer, dated 11-05-2026; SEC file number 028-15744.
  • · No prior-quarter holdings data is included in this filing, so position changes versus Q2 2026 cannot be determined.
MATTEL INC /DE/ 10-Q mixed materiality 7/10

06-11-2026

Mattel reported Q3 2026 net sales of $1,806.7M, up 4.1% YoY from $1,736.0M, with gross profit rising 14.0% to $989.6M and operating income up 25.4% to $476.3M. Diluted EPS jumped 39.8% to $1.23 from $0.88. However, nine-month net sales of $3,794.2M (+5.9%) masked a 5.2% decline in nine-month operating income to $384.5M, driven by a 34.8% surge in advertising and promotion expenses to $360.5M; cash and equivalents fell sharply to $541.4M from $1,242.9M at year-end 2025, and nine-month operating cash flow remained negative at -$113.5M (improved from -$203.3M).

  • · Nine-month 2026 net income of $396.4M included a $147.9M gain on remeasurement of a previously held equity interest, boosting results
  • · Nine-month 2026 net cash used in operating activities was -$113.5M, an improvement from -$203.3M in 2025 but still negative
  • · Cash and equivalents fell to $541.4M at Sep 30, 2026 from $1,242.9M at Dec 31, 2025
  • · Long-term debt rose to $2,335.0M from $2,331.7M at year-end 2025, with no current portion outstanding
  • · Goodwill increased to $1,582.2M from $1,390.2M at year-end, reflecting an acquisition with $193.8M of goodwill and $163.4M of identifiable net assets
  • · Share repurchases totaled $308.4M in nine months 2026 vs $412.5M in 2025
  • · Q3 2026 cost of sales declined 5.8% to $817.1M from $867.7M, driving gross margin expansion
  • · Nine-month other non-operating income of $141.1M vs $12.6M expense in 2025, largely from the remeasurement gain
  • · Weighted-average diluted shares fell to 286.8M from 318.1M YoY due to buybacks
PERSHING SQUARE HOLDCO, L.P. 10-Q negative materiality 7/10

06-11-2026

Pershing Square Holdco reported Q3 2026 total revenue of $56.6M, down 14.5% YoY from $66.2M, as performance fees fell to zero from $3.9M and management fees declined 9.1% to $56.6M. Total expenses surged 82.8% YoY to $76.7M (driven by employee compensation jumping to $70.5M from $5.7M), producing an operating loss of $20.1M versus operating income of $24.2M a year ago and a net loss attributable to PS Inc. of $19.9M (EPS -$0.05) versus net income of $155.5M ($0.39) in Q3 2025. For the nine months, revenue was roughly flat at $168.3M (+0.4% YoY) but net loss attributable to PS Inc. reached $210.2M versus $198.9M income, with unrealized losses on HHH shares (-$55.4M) and PSUS shares (-$53.9M) offsetting a $132.3M prior-year HHH gain.

  • · Nine-month 2026 net loss attributable to PS Inc. was $210.2M versus $198.9M net income in 2025, a swing of over $409M.
  • · Nine-month 2026 total expenses rose 133.9% to $273.4M from $116.9M, including $81.0M profit-sharing partner compensation and $171.9M non-cash equity-based compensation amortization.
  • · Q3 2026 EPS was -$0.05 versus $0.39 in Q3 2025; nine-month EPS was -$0.53 versus $0.50.
  • · Loans payable rose to $294.2M from $34.8M at year-end 2025, with $293.8M net new borrowings and $34.8M repaid.
  • · Cash and cash equivalents fell to $767,680 from $55.4M at Dec 31, 2025; total cash including restricted was $886,615.
  • · Performance fees receivable of $497.3M at year-end 2025 was fully collected (zero at Sept 30, 2026).
  • · Investment in HHH declined 7.7% to $662.6M from $717.9M, with a $55.4M nine-month unrealized loss versus a $132.3M gain in 2025.
  • · New positions established: $196.1M investment in PSUS, $80.0M venture investments, and a $584.7M deferred asset for PS Inc. IPO shares.
  • · Dividends of $48.8M paid to shareholders in 2026; capital distributions of $118.1M paid.
  • · Operating cash flow turned positive at $171.7M versus -$162.9M used in 2025, aided by $497.3M performance fee collections.
  • · Deferred tax liability of $124.8M recorded as of Sept 30, 2026 versus none at year-end 2025.
  • · Company converted from partnership structure to corporate structure (PS Inc.) with 400,000,000 shares outstanding and $1.38B additional paid-in-capital.
BILL Holdings, Inc. 10-Q mixed materiality 7/10

06-11-2026

BILL Holdings reported Q1 FY2027 total revenue of $353.8M, up 12.5% YoY from $314.5M, driven by subscription and transaction fees rising 14.3% to $316.4M, while interest on funds held for customers slipped 0.9% to $37.4M. The company swung to net income of $60.3M (diluted EPS $0.61) from a net loss of $3.0M a year ago, helped by sharp operating expense cuts (R&D -37%, S&M -14.6%, G&A -15.1%) and a $51.2M operating profit versus a $20.7M loss. However, restructuring charges jumped to $24.4M from $8.9M, gross margin compressed to 76.9% from 75.5% on higher service and D&A costs, and the company repurchased $304.9M of stock, reducing shares outstanding to 85.9M from 92.1M at June 30, 2026.

  • · Total assets fell to $9.69B at Sept 30, 2026 from $10.22B at June 30, 2026, driven by lower cash, short-term investments, and funds held for customers
  • · Funds held for customers declined to $4.13B from $4.35B, with matching customer fund deposits liability
  • · Accumulated deficit widened to $2.33B from $2.09B, and accumulated other comprehensive loss grew to $21.5M from $6.4M on unrealized investment losses of $15.1M
  • · Stock-based compensation fell to $40.7M from $58.8M YoY
  • · Impairment of operating lease right-of-use assets and property/equipment of $25.8M recorded in Q1 FY2027 (none prior year)
  • · Net cash provided by operating activities was essentially flat at $96.8M vs $96.9M YoY
  • · Net cash used in financing activities was $550.7M, largely from $312.2M of buybacks and $216.4M customer fund deposit outflows
  • · Provision for expected credit losses on acquired card receivables and other financial assets fell to $10.3M from $12.2M
  • · Acquired card receivables grew to $892.6M from $811.8M
Alphabet Inc. 13F-HR neutral materiality 3/10

06-11-2026

Alphabet Inc. filed its Q3 2026 13F-HR disclosing 31 equity positions valued at a combined $88,346,124,056 as of September 30, 2026, with the largest holdings being SpaceX Class A ($55.5B), Planet Labs ($35.2B), and Arm Holdings ($19.6B). The portfolio is heavily concentrated in a handful of private/space and life-sciences names, while several positions are comparatively small, including Freshworks split across three share classes and minor stakes in Oscar Health and Sana Biotechnology. The filing reflects Alphabet's venture/investment arm holdings rather than operating results, so no period-over-period performance metrics are disclosed.

  • · Portfolio is highly concentrated: SpaceX ($55.5B) and Planet Labs ($35.2B) together account for roughly 99% of total reported value.
  • · Freshworks is held across three separate Class A line items totaling about $143.4M.
  • · Neutron Holdings is reported in two line items totaling about $19.0M.
  • · Filing signed by Marsida Saraci, VP, Corporate Controller and Principal Accounting Officer, on 11-05-2026.
  • · Report period is 09-30-2026; filing date 11-06-2026.
  • · Other included managers listed: GV Management Company, Google LLC, CapitalG II LP, and XXVI Holdings Inc.
Bowman Consulting Group Ltd. 10-Q mixed materiality 7/10

06-11-2026

Bowman Consulting Group reported Q3 2026 gross contract revenue of $148.7M, up 18.0% YoY from $126.0M, and nine-month revenue of $421.3M, up 16.7% from $361.1M. However, profitability deteriorated sharply: Q3 swung to a net loss of $1.988M from net income of $6.618M a year earlier, and nine-month net income fell to a loss of $3.195M from $10.883M, driven by higher other expenses ($4.665M vs $2.018M in Q3) and SG&A growth. Diluted EPS turned negative at -$0.12 for Q3 versus $0.37 prior year, while operating income declined to $3.379M from $5.292M.

  • · Cash and cash equivalents fell to $5.247M from $11.066M at year-end 2025, a $5.819M decrease.
  • · Revolving credit facility borrowings rose to $139.035M from $95.350M at December 31, 2025.
  • · Total liabilities increased to $377.486M from $318.577M, while total assets grew to $641.337M from $579.682M.
  • · Nine-month operating cash flow dropped 65% to $9.262M from $26.471M, partly due to a $24.946M build in contract assets.
  • · Q3 2026 direct payroll costs rose to $53.731M from $45.163M YoY.
  • · Depreciation and amortization increased to $7.848M in Q3 2026 from $6.887M.
  • · Nine-month 2026 net loss attributable to common shareholders was $3.195M versus income of $10.344M prior year.
  • · Treasury stock at cost was $99.475M (5,229,997 shares) as of September 30, 2026.
Canopy Growth Corp 10-Q mixed materiality 7/10

06-11-2026

Canopy Growth reported Q2 FY2027 (three months ended September 30, 2026) net revenue of $81.4M, up 22% YoY from $66.7M, with gross margin improving to $23.4M from $21.9M. However, the company swung to a net loss of $40.7M from $5.0M a year ago, driven by a $18.5M other expense versus $12.1M other income in the prior year, while operating loss widened to $23.0M from $16.9M. Cash and cash equivalents fell to $247.3M from $364.7M at March 31, 2026, reflecting $37.6M of operating cash burn and $71.7M of short-term investment purchases.

  • · Basic and diluted loss per share widened to $(0.10) in Q2 FY2027 from $(0.02) in Q2 FY2026
  • · Weighted average common shares outstanding rose to 423,109,807 from 274,025,102 YoY, diluting per-share results
  • · Selling, general and administrative expenses rose to $39.7M from $36.3M YoY
  • · Share-based compensation more than doubled to $4.0M from $2.0M YoY
  • · Loss on asset impairment and restructuring increased to $2.6M from $0.5M YoY
  • · Excise taxes rose to $18.1M from $16.3M YoY
  • · No ATM equity proceeds in six months ended Sept 30, 2026 versus $281.5M raised in the prior-year period
  • · Interest paid fell to $15.3M from $16.5M in the six-month period
  • · Foreign currency translation turned negative $(1.4M) in Q2 FY2027 versus $6.8M positive in Q2 FY2026
  • · Goodwill held flat at $55.7M; intangible assets declined to $85.5M from $92.4M
Eurizon Asset Management Slovakia, sprav. spol., a.s. 13F-HR neutral materiality 2/10

06-11-2026

Eurizon Asset Management Slovakia, sprav. spol., a.s. filed its Q3 2026 13F-HR holdings report (period ended September 30, 2026), disclosing six US-listed equity positions totaling approximately $6.41 million in reported value. The largest holding is Taiwan Semiconductor Manufacturing sponsored ADS at $2,620,812 (5,745 shares), followed by Alibaba Group at $764,609 (7,110 ADS) and Banco Bradesco preferred ADR at $282,385 (80,223 shares); the smallest positions are HDFC Bank ($80,424) and SK Hynix ($182,309). The portfolio is heavily concentrated in emerging-market and Asian ADRs, with no period-over-period comparison data disclosed in this filing.

  • · All six positions are held via ADRs/ADS and are classified as 'SH' (shares) with 'OTR' (other) discretion and sole voting authority; no put/call options reported.
  • · The filing lists Intesa Sanpaolo S.p.A. as a related entity (file number 028-26259) in the signature block.
  • · Filer is a non-US entity headquartered at Mlynske Nivy 1, Bratislava, Slovakia (ZIP 82004), with SEC file number 028-26165.
  • · TSMC represents roughly 41% of the reported portfolio value, indicating high single-name concentration.
  • · No quarter-over-quarter change data is disclosed in this 13F-HR, so prior-period comparisons cannot be calculated.
Elanco Animal Health Inc 8-K positive materiality 8/10

06-11-2026

Elanco reported Q3 2026 revenue of $1.265 billion, up 11% year-over-year (9% organic constant currency), with reported net income of $18 million versus a $34 million loss a year ago and Adjusted EPS of $0.27 (+42%). Pet Health grew 14% and Cattle rose 17%, but Poultry declined 7% and Contract Manufacturing/Other fell 36%; the company raised full-year 2026 revenue guidance to $5.155-$5.18 billion and Adjusted EPS to $1.17-$1.20 while net leverage improved to 2.9x.

  • · Poultry revenue declined 7% to $201M and Contract Manufacturing/Other fell 36% to $26M, the weakest segments in the quarter
  • · Cash from operations slipped to $216M from $219M a year ago despite higher earnings
  • · Seresto revenue of $49M was negatively impacted by U.S. retailer inventory drawdown
  • · Reported net interest expense rose $7M to $59M due to swap maturities and imputed interest on future revenue sale
  • · Zenrelia U.S. JAK market share grew 7 points YoY; Credelio Quattro U.S. share grew 9 points YoY
  • · Credelio Quattro became Elanco's largest U.S. Pet Health branded product, surpassing Seresto U.S.
  • · Credelio Quattro received positive EMA opinion for EU expansion, launch expected Q1 2027
  • · Befrena full launch planned Q1 2027; ~20% of clinics buying it had never used Zenrelia
  • · FY2026 adjusted gross margin guidance raised to 55.8%-56.0% (100 bps improvement vs prior 50 bps expectation)
  • · Q4 2026 Adjusted EPS guidance of $0.16-$0.19
  • · 2027 early outlook: mid-single digit organic CC revenue growth, high-single digit Adjusted EBITDA growth, low-double digit Adjusted EPS growth
  • · Net leverage ratio decreased 0.7x from 3.6x at December 31, 2025 to 2.9x
Beam Global 8-K negative materiality 6/10

06-11-2026

Beam Global and the sellers of Norway's ScoutDI AS mutually terminated the October 6, 2026 Share Sale and Purchase Agreement after the November 4, 2026 outside closing date passed, citing unfavorable conditions in the U.S. public markets. No cash consideration will be paid and no BEEM shares will be issued, and no termination fee is owed by either party. The companies will instead explore alternative arrangements, including potential U.S. manufacturing of ScoutDI drone systems and distribution of its drone and software products to industrial and defense customers, though no definitive agreement exists.

  • · Purchase Agreement dated October 6, 2026, originally disclosed in an 8-K filed October 7, 2026
  • · Outside closing date was November 4, 2026; closing did not occur by that date
  • · Written termination notices delivered November 5, 2026, effective immediately
  • · No termination fee payable by either Beam Global or the Sellers
  • · Each party bears its own costs and expenses; confidentiality, notices, expenses, governing law and arbitration provisions survive termination
  • · ScoutDI AS is a Norwegian private limited liability company; Husteli AS acted as Sellers' Representative
  • · Common stock trades on NASDAQ Capital Market under symbol BEEM
  • · No definitive agreement for any alternative arrangement has been signed
NIP Group Inc. SC 13D neutral materiality 4/10

06-11-2026

Tang Heng, executive vice president of NIP Group Inc. (NIPG), filed a Schedule 13D disclosing beneficial ownership of 53,337,563 ordinary shares, or approximately 9.4% of the 567,186,133 total ordinary shares outstanding as of October 30, 2026. The position consists of 52,584,563 Class B1 ordinary shares received upon vesting of Restricted Shares under the Amended and Restated 2025 Share Incentive Plan and 753,000 Class A ordinary shares held as ADSs, down from 1,104,590 Class A shares held at the July 2024 IPO. However, Tang Heng granted an irrevocable voting proxy over all 52,584,563 Class B1 shares (about 33.4% of aggregate voting power) to co-founder, co-CEO and chairman Mario Yau Kwan Ho, meaning his economic stake is not matched by independent voting control.

  • · Each Class B ordinary share carries 20 votes versus 1 vote per Class A share, subject to Weighted Voting Right and approval conditions.
  • · Each Class B ordinary share is convertible into one Class A share at the holder's option; Class A shares are not convertible into Class B.
  • · Tang Heng reported no securities transactions in the past 60 days other than as disclosed.
  • · The shares were acquired for investment purposes; the Reporting Person reserves the right to acquire additional securities or change plans.
  • · Company was formerly named ESVF Esports Group Inc. (name change February 16, 2023).
  • · No other person has the right to receive dividends or direct receipt of proceeds from the beneficially owned shares.
PSQ Holdings, Inc. 10-Q mixed materiality 7/10

06-11-2026

PSQ Holdings reported Q3 2026 net revenue of $7.34M, up 66.7% YoY from $4.40M, and narrowed its quarterly net loss to $4.13M from $11.98M a year earlier as G&A fell 60.9%. However, the nine-month picture is weaker: net loss of $16.21M on revenue of $22.63M, with gross margin compressed by cost of revenue rising 222.9% to $10.10M, and cash and equivalents plunged to $3.84M from $14.64M at year-end 2025, leaving total stockholders' equity at just $1.70M versus $13.44M.

  • · Nine-month cost of revenue rose 222.9% to $10.10M versus $3.13M, outpacing revenue growth and compressing gross margin
  • · Nine-month R&D fell 35.4% to $2.08M and sales and marketing fell 11.6% to $4.10M
  • · Nine-month depreciation and amortization rose 31.3% to $5.22M from $3.97M
  • · Interest expense rose to $2.89M for nine months versus $2.61M a year earlier
  • · Loss from discontinued operations narrowed to $0.45M for nine months from $7.19M
  • · Net cash used in operating activities improved to $8.17M from $17.37M
  • · Intangible assets declined to $11.62M from $14.57M; goodwill held flat at $10.93M
  • · Class C Common Stock fully converted/cancelled during 2026; zero Class C shares outstanding at Sep 30, 2026
  • · Reverse stock split adjusted prior share counts (e.g., Dec 31, 2025 Class A from 46,492,639 to 3,099,509)
GRAY MEDIA, INC 8-K neutral materiality 2/10

06-11-2026

Gray Media, Inc. filed an 8-K on November 6, 2026, disclosing under Item 7.01 (Regulation FD) that it will meet with and present to prospective investors from time to time, using slides furnished as Exhibit 99.1. The filing contains no financial results, guidance figures, or transaction terms — only the investor-meeting disclosure and exhibit list, signed by EVP & CFO Jeffrey R. Gignac. No quantitative performance data was provided, so no period-over-period comparisons are possible.

  • · Investor meetings and presentations to prospective investors begin on November 6, 2026 and may occur from time to time thereafter
  • · Exhibit 99.1 consists of slides that may be used in and/or referenced during such investor meetings
  • · Item 7.01 information is furnished, not filed, and is not incorporated by reference into other filings unless expressly stated
  • · Class A common stock trades on NYSE under GTN.A; common stock trades on NYSE under GTN
  • · Company is not an emerging growth company (box unchecked)
  • · Exhibit 104 is the Cover Page Interactive Data File embedded within the Inline XBRL document
Bloomin' Brands, Inc. 8-K mixed materiality 7/10

06-11-2026

Bloomin' Brands reported Q3 2026 total revenues of $944.3M, up 1.7% YoY from $928.8M, helped by $13.2M of gift card breakage revenue from an accounting estimate change and higher comparable sales. GAAP operating income margin swung to 2.0% from (3.9)% on lower impairment/closure costs, but adjusted operating income margin fell to 0.3% from 0.8% and adjusted diluted EPS deteriorated to $(0.17) from $(0.03). Despite the adjusted EPS decline, the company raised full-year diluted EPS guidance to $1.06-$1.11 from $0.85-$0.95 while narrowing U.S. comp sales guidance to 1%-1.5% from 1%-2%.

  • · Q3 2026 adjusted diluted EPS of $(0.17) vs $(0.03) in Q3 2025, a $0.14 deterioration
  • · FY2026 diluted EPS guidance raised to $1.06-$1.11 from $0.85-$0.95; adjusted diluted EPS guidance raised to $0.97-$1.02 from $0.90-$1.00
  • · FY2026 U.S. comparable restaurant sales guidance narrowed to 1%-1.5% from 1%-2%
  • · Q4 2026 outlook: U.S. comp sales 0%-1%, diluted EPS $0.07-$0.12, adjusted diluted EPS $0.07-$0.12
  • · Fleming's Prime Steakhouse comparable sales were flat (0%) in Q3 2026
  • · Year-to-date 2026 net income attributable to Bloomin' Brands was $84.816M vs $21.712M in 2025
  • · Q3 2026 GAAP income from operations was $18.584M vs a loss of $36.420M in Q3 2025
  • · Impairments, closures and disposal of assets were a net benefit of $0.856M in Q3 2026 vs $33.236M expense in Q3 2025
  • · G&A expense declined to $54.262M from $59.103M YoY
  • · Outback Turnaround has delivered five consecutive quarters of YoY improvement in Outback guest scores
  • · Out West (franchisee) initiated Chapter 11 proceedings; Bloomin' has an offer to buy Out West's restaurants pending acceptance
  • · Company operates more than 1,440 restaurants in 46 states, Guam and 12 countries
  • · Q3 2026 adjustments of $(0.15) primarily reflect gift card breakage revenue accounting estimate change
AMN HEALTHCARE SERVICES INC 10-Q mixed materiality 8/10

06-11-2026

AMN Healthcare reported Q3 2026 revenue of $717.3M, up 13.0% YoY from $634.5M, with net income rising 14.0% to $33.4M and diluted EPS of $0.83 versus $0.76. Nine-month revenue jumped 39.7% to $2,768.9M and net income swung to $116.7M from a $88.0M loss, though the prior-year period was depressed by a $109.5M goodwill impairment and $18.3M long-lived asset impairment. However, gross margin compressed to 32.0% in Q3 2026 from 29.1% a year earlier on a dollar basis improving, while SG&A rose 7.7% and operating income grew only 6.1% to $50.5M, indicating margin pressure despite top-line growth.

  • · Gross margin improved to 32.0% in Q3 2026 from 29.1% in Q3 2025
  • · Nine-month 2026 operating income was $194.6M versus a $63.6M operating loss in 2025
  • · Cash and equivalents surged to $256.0M from $34.0M at year-end 2025
  • · Revolving credit facility fully repaid to zero from $25.0M at December 31, 2025
  • · Nine-month 2026 cash paid for income taxes rose to $66.3M from $8.3M
  • · Repurchased 336 thousand shares for $10.7M during 2026
  • · Diluted weighted average shares rose to 40,165 thousand from 38,693 thousand YoY
  • · Nine-month 2026 D&A declined to $101.6M from $119.4M
Alpha Metallurgical Resources, Inc. 8-K mixed materiality 7/10

06-11-2026

Alpha Metallurgical Resources reported a Q3 2026 net loss of $9.3 million ($0.73 per diluted share), narrowing from a $12.3 million loss in Q2 2026 but widening from a $5.5 million loss in Q3 2025. Adjusted EBITDA rose to $29.4 million from $25.6 million QoQ but fell sharply from $41.7 million a year earlier, while Met segment cost of coal sales per ton climbed to $106.93 from $103.07 QoQ amid continued cost pressures. The company committed 3.5 million tons of met coal to domestic customers for 2027 at an average $135.48 per ton and issued 2027 guidance of 14.3-15.7 million total tons, while flagging a lengthy replacement timeline for storm-damaged stacker reclaimer equipment at Dominion Terminal Associates.

  • · Q3 2026 Met segment realization per ton was $121.09 vs $118.71 in Q2 2026
  • · Domestic met tons sold 1.0 million at $136.17/ton (27% of met tons); Australian-indexed export 0.8 million at $150.46/ton; other export 1.8 million at $107.03/ton
  • · 2027 guidance: met coal 13.1-14.1 million tons, thermal 1.2-1.6 million tons, total 14.3-15.7 million tons
  • · 2027 cost of coal sales guidance $104.00-$110.00 per ton vs 2026 guidance $103.00-$107.00
  • · 2027 SG&A $53-59 million; idle operations $25-33 million; DD&A $148-162 million; capex $145-165 million; equity affiliate contributions $28-37 million; cash tax rate 0-5%
  • · 2026 guidance: met 13.2-14.0 million tons, thermal 1.0-1.4 million tons, total 14.2-15.4 million tons
  • · As of October 29, 2026, ~87% of 2026 met coal committed and priced at $126.69/ton; thermal fully committed at $76.06/ton
  • · 2027 committed/priced: met 26% at $134.46/ton (domestic 3.5 million at $135.48; export 0.1 million at $100.32); thermal 80% at $78.47/ton
  • · Share repurchases averaged approximately $166.31 per share
  • · No amounts borrowed under ABL as of September 30, 2026
  • · Stacker reclaimer at DTA damaged by June storm; lengthy replacement timeline expected but no significant capital outlays anticipated
Mandatum Life Insurance Co Ltd 13F-HR neutral materiality 3/10

06-11-2026

Mandatum Life Insurance Co Ltd filed its Q3 2026 13F-HR disclosing 80 total holdings valued at $571,673,278 as of September 30, 2026. The portfolio is heavily concentrated in broad-market ETFs, led by iShares Core S&P 500 ETF ($209.9M) and Vanguard S&P 500 ETF ($54.7M), with large-cap tech anchors including Alphabet ($18.3M), Cisco ($13.5M) and Microsoft ($12.7M). The filing shows two new positions added during the quarter (Airbnb and Roundhill Memory ETF), while several legacy holdings such as Apple ($755K) and Eli Lilly ($257K) remain comparatively small allocations.

  • · Filing is a 13F-HR for the period ending 09-30-2026, filed 11-06-2026 (CIK 0001664324, SEC File 028-17135).
  • · All 80 positions are held in sole voting/dispositive capacity (no shared or other-manager discretion reported).
  • · Portfolio is ETF-heavy: the two S&P 500 index ETFs alone (iShares $209.9M + Vanguard $54.7M) represent roughly 46% of total reported value.
  • · Other sizable ETF allocations include iShares Core MSCI Pacific ($24.8M), iShares Russell 2000 ($11.7M) and iShares USA Min Vol ($4.0M).
  • · Notable single-stock holdings include Bank of America ($7.0M), Target ($7.0M), Visa ($6.7M), Disney ($5.8M), Gap ($5.7M) and Humana ($5.3M).
  • · Small/legacy positions include Plug Power ($108K), Viomi Technology ($58K) and Grab Holdings ($145K).
  • · Two positions flagged as newly ADDED this quarter: Airbnb ($3.6M) and Roundhill Memory ETF ($229K).
Anika Therapeutics, Inc. 8-K mixed materiality 7/10

06-11-2026

Anika reported Q3 2026 total revenue of $30.6M, up 10% YoY from $27.8M, with Commercial Channel revenue up 17% to $14.0M and OEM Channel up 5% to $16.6M; gross margin improved to 62% from 56%. However, GAAP loss from continuing operations was $0.3M ($0.02 per diluted share), and the FDA notified the company in October that its Hyalofast PMA application is not approvable. The company raised the low end of 2026 total revenue guidance to 6%-10% growth and raised 2026 adjusted EBITDA margin guidance to 15%-17%, but lowered Commercial Channel growth guidance to 9%-13% from 12%-18% and guided 2027 total revenue growth to flat to 5%.

  • · FDA notified Anika in October that the Hyalofast PMA application is not approvable, primarily based on clinical data in the submission
  • · 2026 Commercial Channel revenue growth guidance lowered to 9%-13% from 12%-18% previously
  • · 2027 total company revenue growth guidance is flat to 5%, with OEM Channel expected flat to modestly lower
  • · 2026 OEM Channel revenue growth guidance raised to 5%-9% from 0%-5% previously
  • · 2026 total company revenue growth guidance raised to 6%-10% from 5%-10% previously
  • · 2026 Adjusted EBITDA margin guidance raised to 15%-17% from 13%-17% previously
  • · Cingal NDA submission expected before year-end 2027
  • · New 10-year Hyvisc distribution agreement with Boehringer Ingelheim includes higher transfer pricing, a royalty on end-market sales, higher contractual purchases, and upfront and milestone payments
  • · Integrity revenue grew despite a slower than anticipated Q3 elective surgery market
  • · Cross-link line unit volumes now more than 50% above 2022 levels
  • · FDA approved new aseptic manufacturing processes and validated a second cross-link filler
  • · Adjusted diluted EPS from continuing operations was $0.29
SIMON PROPERTY GROUP INC. 10-Q mixed materiality 8/10

06-11-2026

Simon Property Group reported Q3 2026 total revenue of $1.81B, up 13.3% YoY from $1.60B, driven by lease income rising 15.7% to $1.68B. However, consolidated net income fell 19.6% to $565.3M and net income attributable to common stockholders declined 17.7% to $499.0M, with EPS down to $1.54 from $1.86, pressured by a $129.6M unrealized fair-value loss on equity/derivative instruments versus a $2.2M gain prior year and higher interest expense (+18.4%). For the nine months, revenue rose 17.3% to $5.36B while net income attributable to common stockholders slipped 7.3% to $1.46B.

  • · Operating income before other items was essentially flat, down 1.0% YoY to $804.5M in Q3 2026 from $812.9M.
  • · Depreciation and amortization jumped 50.8% YoY to $510.8M in Q3 2026 from $338.6M.
  • · Total stockholders' equity fell to $4.09B at Sept 30, 2026 from $5.21B at Dec 31, 2025, and accumulated deficit widened to $(5.35B) from $(4.61B).
  • · The company repurchased $572.5M of treasury stock in the nine months ended Sept 30, 2026 versus none in the prior-year period.
  • · Nine-month 2026 debt issuance was $10.02B against $9.73B of repayments, versus $3.07B issuance and $2.19B repayment in 2025.
  • · Cash and cash equivalents declined to $569.9M from $823.1M at year-end 2025.
  • · Investment in Klépierre at equity decreased to $1.34B from $1.51B at Dec 31, 2025.
  • · Nine-month 2026 preferred dividends and distributions to stockholders were $2.17B versus $2.08B in 2025.
TREACE MEDICAL CONCEPTS, INC. 10-Q mixed materiality 7/10

06-11-2026

Treace Medical Concepts reported Q3 2026 revenue of $48.253M, down 3.9% YoY from $50.214M, while nine-month revenue fell 6.2% to $140.827M from $150.171M. Net loss narrowed to $12.566M in Q3 (from $16.288M) and to $46.400M for nine months (from $49.608M), helped by a 9.9% cut in operating expenses, though gross margin slipped to 79.5% from 79.1% and interest expense rose 18.4% YoY. Cash and equivalents declined to $7.760M from $10.708M at year-end, total stockholders' equity fell to $61.646M from $87.332M, and inventories rose 17.4% to $42.304M while accounts receivable dropped 28.3%.

  • · Gross margin was 79.5% in Q3 2026 vs 79.1% in Q3 2025, a slight improvement
  • · Nine-month operating loss narrowed to $43.657M from $48.232M
  • · Net cash used in operating activities improved to $0.713M for 9M 2026 from $7.944M in 9M 2025
  • · Interest income fell to $0.387M in Q3 2026 from $0.634M YoY
  • · Total liabilities rose to $117.654M from $103.249M at December 31, 2025
  • · Accounts payable increased to $14.284M from $6.726M at year-end
  • · Share-based compensation declined to $21.428M for 9M 2026 from $26.268M
  • · Treasury shares withheld for taxes increased to 348,299 shares from 165,513
TELUS CORP 6-K neutral materiality 3/10

06-11-2026

TELUS Corporation filed a Form 6-K on November 6, 2026, incorporating by reference its Consolidated Financial Statements (Exhibit 99.1) and Management's Discussion and Analysis (Exhibit 99.2) into its existing F-10, F-3D, and S-8 registration statements. The filing itself contains no financial figures, performance metrics, or period-over-period comparisons — only cover-page, signature, and exhibit-index information. As a result, no positive, negative, or flat performance data can be assessed from this document.

  • · Filing is a Form 6-K for the month of November 2026, Commission File Number 001-15144
  • · Registrant files annual reports under Form 40-F (not Form 20-F)
  • · Exhibits incorporated by reference: 99.1 Consolidated Financial Statements and 99.2 Management's Discussion and Analysis
  • · Incorporated into registration statements on Form F-10 (File No. 333-291929), Form F-3D (File No. 333-258770), and Form S-8 (File Nos. 333-291404, 333-268186, 333-181463, 333-125486)
  • · Principal executive office: 23rd Floor, 510 West Georgia Street, Vancouver, British Columbia V6B 0M3, Canada
  • · Signed by Andrea Wood, EVP and Chief Legal and Governance Officer, dated November 6, 2026
Canopy Growth Corp 8-K mixed materiality 7/10

06-11-2026

Canopy Growth reported Q2 FY2027 consolidated net revenue of $81.4M, up 22% YoY, led by a 30% increase in the Cannabis segment and a 141% surge in international cannabis revenue to $12.3M (from $5.1M) on strong Germany and Poland medical sales. However, Storz & Bickel revenue fell 4% to $15.1M, consolidated gross margin contracted to 29% from 33% (adjusted gross margin 31% vs 33%) on lower VAC reimbursement rates, and net loss widened by $35.7M due to $35.8M of Canopy USA fair value charges. Adjusted EBITDA loss narrowed 6% to $2.9M and free cash outflow improved to $15.5M from $19.2M.

  • · Canada medical cannabis growth was partially offset by the Canadian government's reduction in the VAC reimbursement rate
  • · Canada adult-use growth was partially offset by declines in opportunistic bulk sales
  • · SG&A expenses rose 9% YoY due to MTL Cannabis operations, offset by headcount reductions
  • · Storz & Bickel gross margin held at 39% vs 38% despite revenue decline, aided by cost efficiencies and product mix
  • · Smiths Falls is described as Canada's only EU GMP-certified site combining softgel manufacturing with primary packaging
  • · Kincardine, Ontario cultivation facility received renewed EU GMP certification
  • · Conference call scheduled 10:00 AM ET on November 6, 2026; webcast replay available until February 4, 2027
  • · Company expects to reach positive adjusted EBITDA during fiscal 2027
DraftKings Inc. 10-Q mixed materiality 8/10

06-11-2026

DraftKings reported Q3 2026 revenue of $1,329,063 thousand, up 16.2% YoY from $1,144,019 thousand, but the net loss attributable to common stockholders widened sharply to $468,720 thousand from $256,788 thousand as sales and marketing surged 68.1% to $605,664 thousand and operating loss deepened to $493,129 thousand from $271,890 thousand. Nine-month revenue rose 8.7% to $4,418,374 thousand while the net loss ballooned to $515,260 thousand from $132,716 thousand, and operating cash flow collapsed to $63,026 thousand from $342,382 thousand. Loss per share worsened to $0.94 from $0.52 in the quarter and to $1.04 from $0.27 year-to-date, with total stockholders' equity falling to $179,636 thousand from $631,461 thousand at year-end 2025.

  • · Product and technology expense rose 19.8% YoY to $137,392 thousand in Q3 2026
  • · General and administrative expense rose 14.3% YoY to $179,125 thousand in Q3 2026
  • · Nine-month 2026 sales and marketing rose 41.9% to $1,329,934 thousand from $937,237 thousand
  • · Interest expense, net improved to $11,383 thousand in Q3 2026 from $19,573 thousand
  • · Other gain, net was $25,790 thousand in Q3 2026 versus $16,720 thousand a year earlier
  • · Income tax provision of $7,274 thousand in Q3 2026 versus a $12,065 thousand benefit in Q3 2025
  • · Acquisition total consideration of $84,789 thousand including $37,785 thousand contingent consideration and $28,708 thousand equity consideration
  • · Goodwill of $40,195 thousand recognized on the acquisition; intangible assets acquired of $58,090 thousand
  • · Nine-month 2026 investing outflow of $177,430 thousand versus $116,109 thousand, driven by $113,460 thousand internally developed software costs
  • · Financing activities generated $179,152 thousand in nine months 2026, including $687,819 thousand net Term B Loan proceeds
  • · Total amortized intangible assets net of $809,503 thousand at September 30, 2026 versus $889,201 thousand at December 31, 2025
  • · Future minimum payments total $2,236,000 thousand, with $958,000 thousand due in 2028
  • · Cash reserved for users increased $87,571 thousand in nine months 2026 versus a $50,088 thousand decrease a year earlier
  • · Stock-based compensation of $233,794 thousand in nine months 2026, down slightly from $236,020 thousand
Optimum Communications, Inc. 10-Q/A negative materiality 9/10

06-11-2026

Optimum Communications filed a 10-Q/A restating H1 2026 results, which included a $2.7B impairment of indefinite-lived cable franchise rights that drove a net loss of $2,451,676 thousand ($2.45B) versus $171,927 thousand in H1 2025. Revenue declined 4.9% YoY to $4,089,071 thousand for the six months and 5.8% to $2,023,703 thousand in Q2, while Q2 operating income fell to $166,049 thousand from $311,123 thousand. Liquidity improved with cash rising to $1,296,270 thousand from $1,012,201 thousand, but total debt remains heavy at roughly $26.6B and stockholders' deficiency widened to $(4,354,602) thousand.

  • · Indefinite-lived cable franchise rights were written down to $8,900,000 thousand from $11,600,000 thousand, reflecting a $2,700,000 thousand impairment.
  • · Total assets fell to $28,080,616 thousand from $30,703,838 thousand at December 31, 2025.
  • · Accumulated deficit widened to $(4,592,914) thousand from $(2,141,238) thousand.
  • · Deferred tax liability declined to $2,884,672 thousand from $3,801,088 thousand, producing an $807,935 thousand income tax benefit in H1 2026.
  • · Current debt jumped to $4,147,837 thousand from $60,842 thousand, signaling a large near-term maturity or reclassification.
  • · H1 2026 financing activities generated $447,496 thousand, including $2,856,954 thousand of new long-term debt proceeds against $2,544,621 thousand of repayments.
  • · Basic and diluted weighted average shares fell to 445,703 thousand in Q2 2026 from 467,744 thousand a year earlier.
  • · Treasury stock rose to $(57,411) thousand from $(10) thousand, reflecting 11,815,481 Class A and 74,153,348 Class B shares held.
  • · Accounts receivable allowance for credit losses declined to $27,505 thousand from $35,389 thousand.
  • · No cash dividends were declared in either period.
PETERSON WEALTH MANAGEMENT 13F-HR neutral materiality 3/10

06-11-2026

Peterson Wealth Management filed its Q3 2026 13F-HR disclosing 185 total holdings valued at $217,764,204 as of September 30, 2026. The portfolio is heavily concentrated in broad-market and sector ETFs, led by SPDR S&P 500 ETF Trust ($32.56M), Invesco QQQ ($34.63M), iShares Treasury Floating Rate Bond ETF ($18.56M), Vanguard Dividend Appreciation ETF ($16.13M), and Microsoft ($10.19M). The filing is a routine quarterly holdings disclosure with no period-over-period comparison data provided, so no growth or decline metrics can be calculated.

  • · Portfolio is dominated by ETFs and index funds, with the top five positions (Invesco QQQ $34.63M, SPDR S&P 500 $32.56M, iShares Treasury Floating Rate Bond $18.56M, Vanguard Dividend Appreciation $16.13M, Microsoft $10.19M) accounting for roughly 51% of total reported value.
  • · Notable small speculative/emerging-tech positions include iShares Bitcoin Trust ETF ($54,441), CoreWeave ($35,571), Rocket Lab ($12,194), Archer Aviation ($6,213), Oklo ($16,104), NuScale Power ($3,555), and D-Wave Quantum ($7,457).
  • · Several positions are nominal or near-zero value, including Home Depot (1 share, $381), First Trust Managed Municipal ETF (0 shares, $14), and First Trust Institutional Preferred Securities ETF (5 shares, $86).
  • · Filing signed by N Jess Peterson, Chief Compliance Officer, on November 06, 2026; report period September 30, 2026; SEC file number 028-19661.
  • · No prior-quarter holdings data is included in this filing, so quarter-over-quarter position changes cannot be determined from the document.
COMPANHIA DE SANEAMENTO BASICO DO ESTADO DE SAO PAULO-SABESP 6-K mixed materiality 8/10

06-11-2026

SABESP reported 3Q26 consolidated net revenue of R$10,141 million, up 7.6% YoY, with adjusted net revenue from core services rising 9.0% to R$5,958 million on a +7.7% net price effect and +2.1% volume growth. Adjusted EBITDA grew 13.8% YoY to R$3,648 million (61% margin), but reported net income fell 35.7% YoY to R$1,388 million and adjusted net income declined 13.8% to R$1,107 million, as 3Q25 benefited from a non-recurring R$1.5 billion precatórios gain while interest expenses rose on a larger debt balance. Capex rose 13.8% YoY to R$4,528 million in the quarter and 14.9% to R$11,986 million YTD, funded partly by R$6.3 billion higher debt, while net financial result swung to a R$1,222 million expense from a R$707 million gain a year earlier.

  • · 3Q26 costs and expenses rose 2.4% YoY to R$2,325 million, driven by R$112 million higher power costs (+37.2%) and R$82 million higher allowance for doubtful accounts (+106.1%), partly offset by R$147 million lower personnel costs (-21.4%).
  • · 9M26 net income fell 20.3% YoY to R$4,601 million and 9M26 net financial result was a R$3,264 million expense versus near-zero a year earlier.
  • · 9M26 billed volume rose only 0.6% YoY to 3,303 million m³, with industrial volume down 6.2% and 'Others' down 18.1%.
  • · Water Capex jumped 47.2% YoY in 3Q26 to R$1,701 million while sewage Capex was roughly flat at R$2,827 million (+0.1%).
  • · Universalization progress: 118% of the 2024-2026 U-Factor target for new water units, 103% for new sewage units and 89% for units connected to sewage treatment.
  • · Net cash from operating activities fell to R$6,255 million in 9M26 from R$7,454 million in 9M25, while free cash flow from operations dropped to R$2,127 million in 3Q26 from R$3,173 million.
  • · Basic and diluted EPS was R$0.39 in 3Q26 versus R$0.63 in 3Q25; adjusted core EPS was R$0.31 versus R$0.38.
  • · The company acquired EMAE in January 2026 and recorded R$911 million for acquisition of non-controlling interests in 9M26.
INLIF Ltd 6-K/A neutral materiality 2/10

06-11-2026

INLIF Limited filed Amendment No. 1 on Form 6-K/A solely to disclose the new CUSIP number (G4809B 103) for its Class A ordinary shares following its completed migration from the Cayman Islands to the British Virgin Islands on November 2, 2026. The shares continue to trade on the Nasdaq Capital Market under the symbol "INLF." The filing contains no financial results, revenue, or operating metrics, and does not amend or update any other disclosure from the Original Report furnished November 4, 2026.

  • · Migration completed November 2, 2026, via deregistration as a Cayman Islands exempted company and continuation as a BVI business company under the BVI Business Companies Act, 2004
  • · Original Report was furnished to the SEC on November 4, 2026; this Amendment was filed November 6, 2026
  • · SEC file number 001-42456; fiscal year end December 31; incorporated in jurisdiction code D8 (British Virgin Islands)
  • · Company files annual reports under Form 20-F
  • · Principal executive offices located at No. 88, Hongsi Road, Yangxi New Area, Honglai Town, Nan'an City, Quanzhou, People's Republic of China
  • · Amendment does not reflect events occurring after furnishing of the Original Report
QIAGEN N.V. SC 13G/A neutral materiality 2/10

06-11-2026

Wellington Management Group LLP filed a Schedule 13G/A disclosing beneficial ownership of 1,869,523 shares of QIAGEN N.V. common stock, representing 0.9% of the class as of October 30, 2026. The filing shows sole voting power over 1,749,917 shares and sole dispositive power over 1,869,523 shares, with no shared voting or dispositive power reported. The holdings are held in the ordinary course of business by clients of Wellington's investment advisers and are not intended to influence control of the issuer.

  • · Filing is a Schedule 13G/A under Rule 13d-1(b), indicating a passive institutional investor classification
  • · Date of event (as of change): October 30, 2026; filing date November 6, 2026
  • · QIAGEN N.V. is incorporated in the Netherlands (Venlo), SEC file number 005-54659, CIK 0001015820
  • · Wellington Management Group LLP is a Massachusetts entity (CIK 0000902219)
  • · No single client is known to have rights to more than 5% of the class except as noted (Not Applicable)
  • · Joint filing agreement executed by all three Wellington entities on November 6, 2026
  • · Securities were acquired and held in the ordinary course of business, not for the purpose of changing or influencing control
Merit Financial Group, LLC 13F-HR neutral materiality 3/10

06-11-2026

Merit Financial Group, LLC filed its Q3 2026 13F-HR disclosing $17,906,083,461 in total holdings across 12,256 positions as of September 30, 2026. The portfolio is highly diversified, spanning mega-cap names like AbbVie ($23.4M), Abbott ($4.5M), Adobe ($5.4M), AMD ($27.4M) and Accenture ($2.1M) alongside numerous small-cap and ETF positions. The filing is a routine quarterly holdings disclosure with no period-over-period comparison data included, so no growth or decline metrics can be derived from the document itself.

  • · Filing is for the period ended September 30, 2026, filed November 6, 2026
  • · Filer CIK 0001621225; SEC file number 028-18446; CRD 000142457
  • · Business address: 2400 Lakeview Parkway, Suite 550, Alpharetta, GA 30009
  • · Former name: Merit Financial Advisors, LLC (changed 2014-10-01)
  • · Portfolio includes options positions, e.g., AbbVie 900 Put shares and AMD 100 Put shares, plus Affirm 400 Call shares
  • · Holdings are split between sole-discretion (SOLE) and other-manager (OTR) designations across 19 other managers
  • · No period-over-period comparison data is provided in a 13F-HR, so no YoY/QoQ change metrics can be computed
BlackRock TCP Capital Corp. SC 13D/A neutral materiality 6/10

06-11-2026

Saba Capital Management, L.P. (with Saba Capital Management GP, LLC and Boaz R. Weinstein) filed Amendment No. 1 to its Schedule 13D, disclosing beneficial ownership of 5,986,934 common shares of BlackRock TCP Capital Corp., equal to 7.14% of the 83,902,775 shares outstanding as of 11/5/26. The reporting persons paid approximately $24,194,242 to acquire the shares, with all purchases made in the open market between 10/14/2026 and 11/5/2026 at prices ranging from $3.96 to $4.37. The amendment updates Items 3, 5 and 7 and reflects continued accumulation, including a large 698,126-share buy on 11/5/2026 at $4.10.

  • · Open-market purchases from 10/14/2026 to 11/5/2026 ranged in price from $3.96 (10/26/2026) to $4.37 (11/4/2026)
  • · Largest single-day purchase: 698,126 shares on 11/5/2026 at $4.10
  • · Other notable buys: 187,306 shares on 11/4/2026 at $4.37; 175,844 shares on 11/3/2026 at $4.22; 119,870 shares on 10/14/2026 at $4.07
  • · Smallest purchase: 800 shares on 10/15/2026 at $4.12
  • · All trades were effected in the open market
  • · Funds for purchases derived from investor subscription proceeds, capital appreciation, and margin account borrowings
  • · This is Amendment No. 1 to the Schedule 13D originally filed 10/14/26, amending Items 3, 5 and 7
  • · Reporting persons disclaim beneficial ownership beyond their pecuniary interest
ELLSWORTH GROWTH & INCOME FUND LTD SC 13D/A neutral materiality 6/10

06-11-2026

Saba Capital Management, L.P., together with affiliates Saba Capital Management GP, LLC and Boaz R. Weinstein, filed Amendment No. 7 to its Schedule 13D, reporting beneficial ownership of 1,821,810 common shares of Ellsworth Growth & Income Fund Ltd, representing 13.48% of the 13,514,217 shares outstanding as of November 2, 2026. The aggregate purchase price for the shares was approximately $15,253,006. Saba acquired the shares for investment purposes, believing they are undervalued, and may engage in discussions with management and the Board regarding governance, board appointments, and strategic alternatives including potential liquidation or conversion to open-end status; however, no specific agreements with third parties have been reached.

  • · Reporting Persons may seek to influence the Issuer to engage in share buy-backs, tenders, and liquidations and/or to change its governance, investment strategy and/or investment manager (which may be the Reporting Person).
  • · Reporting Persons may nominate one or more individuals as nominees for election to the Board.
  • · All transactions in the past 60 days were open market purchases; no sales were reported.
  • · The percentages are based on 13,514,217 shares outstanding as of 11/2/26, as disclosed in the company's N-2 filed 11/4/26.
TREDEGAR CORP 8-K negative materiality 8/10

06-11-2026

Tredegar reported a Q3 2026 net loss from continuing operations of $(2.8) million, or $(0.08) per diluted share, a sharp reversal from net income of $7.1 million ($0.20/share) in Q3 2025, driven by an 84.9% collapse in Aluminum Extrusions EBITDA to $2.5 million and a 35.6% decline in High Performance Films EBITDA to $4.6 million. Consolidated EBITDA from ongoing operations fell 77% YoY to $4.1 million from $18.1 million, while net sales at Aluminum Extrusions rose 9.1% to $177.3 million on metal cost pass-through despite an 11.6% volume decline. Nine-month net income from continuing operations declined to $8.3 million ($0.24/share) from $9.6 million ($0.28/share), with ongoing-operations net income down to $10.0 million from $14.6 million.

  • · FIFO timing mismatch on aluminum raw material costs resulted in a $2.8 million charge in Q3 2026 versus a $4.3 million benefit in Q3 2025
  • · Aluminum Extrusions contribution margin fell $13.1 million YoY, including $4.4 million from lower volume and $2.1 million from higher labor rates
  • · Q3 2026 Aluminum Extrusions EBIT from ongoing operations was $(1.7) million versus $12.6 million in Q3 2025
  • · High Performance Films EBIT from ongoing operations fell 40.4% YoY to $3.6 million
  • · Company expects to begin realizing One Tredegar benefits in Q1 2027
  • · Conflict-driven disruptions in the Strait of Hormuz since March 2026 constrained aluminum shipments and raised costs; company secured nearly all anticipated 2026 aluminum supply requirements
  • · Architecture Billings Index remained below 50 during 2026 with a sharp decrease in September 2026
  • · Nonresidential building and construction represented approximately 51% of Aluminum Extrusions volume
  • · Bonnell Aluminum 2026 capex projected at $17 million, including $4 million for productivity projects and $13 million for continuity of operations
  • · Nine-month 2026 High Performance Films net sales declined 6.7% to $70.9 million
PLAINS ALL AMERICAN PIPELINE LP 8-K mixed materiality 8/10

06-11-2026

Plains All American reported Q3 2026 net income attributable to PAA of $363 million, down 18% YoY from $441 million, and net cash from operations of $669 million (down 18%), while Adjusted EBITDA attributable to PAA rose 6% to $711 million and Adjusted net income rose 12% to $373 million. Diluted net income per common unit fell to $(0.06) from $0.55 (down 111%), and diluted adjusted net income per unit declined 110% to $(0.04), reflecting the preferred unit redemption and junior subordinated notes issuance. The company declared a $0.4175/unit distribution (+10% YoY, ~7% yield), closed the ~$585 million Silver Creek acquisition, expanded its Permian JV by ~270,000 dedicated acres, and reaffirmed full-year 2026 Adjusted EBITDA guidance of $2.880 billion +/- $50 million.

  • · Nine-month 2026 net income attributable to PAA jumped 115% to $2,345 million, but nine-month diluted adjusted net income per common unit fell 34% to $0.75 from $1.14
  • · Nine-month net cash from operating activities declined 5% to $2,042 million
  • · Q3 2026 Adjusted EBITDA gains were partially offset by Permian long-haul contract rate resets to market in 2025, higher environmental remediation and property tax costs, and lost contributions from the divested Canadian NGL Business
  • · Pro forma leverage ratio at quarter-end was ~3.6x
  • · Balance sheet optimization expected to add ~$0.09/unit of annual distributable cash flow accretion
  • · Canadian NGL Business sold to Keyera Corp. on May 12, 2026; nine-month 2026 free cash flow includes ~$3.527 billion net proceeds from the sale
  • · Nine-month 2025 free cash flow included an $865 million net cash outflow for bolt-on acquisitions
  • · Company reorganized from two segments (Crude Oil and NGL) into one consolidated segment during Q3 2026
  • · New Permian JV agreements are 10-year terms with a large integrated producer, ~225 mbbl/d gross volumes starting Q4 2027
  • · Conference call scheduled 9:00 a.m. CT on November 6, 2026
ForthRight Wealth Management, LLC 13F-HR neutral materiality 3/10

06-11-2026

ForthRight Wealth Management, LLC filed its Q3 2026 13F-HR disclosing 82 holdings with a total reported value of $420,995,986 as of September 30, 2026. The portfolio is heavily ETF-weighted, led by large positions in Schwab US Dividend Equity ETF ($43,447,450), Vanguard S&P 500 ETF ($53,942,006), and iShares Core S&P US Value ($33,598,246), alongside sizable fixed-income and international allocations. Individual equity exposure is comparatively modest, with Apple ($3,349,421) and Visa ($3,144,273) among the largest single stocks.

  • · All 82 positions are held solely (SOLE voting authority) with no shared or discretionary-other voting reported.
  • · Portfolio is ETF-heavy: the ten largest positions are predominantly ETFs, with individual equities representing a minority of total value.
  • · Largest single-stock holdings are Apple ($3,349,421), Visa ($3,144,273), Marathon Petroleum ($3,811,058), and Progressive ($1,529,533).
  • · Fixed-income and municipal exposure includes Vanguard Intermediate Term ($25,300,002), JPMorgan Intl Bd Opp ($23,574,261), JPMorgan Core Plus Bd ($15,183,808), iShares National Muni ($11,256,272), and Vanguard Tax Exempt Bd ($2,941,415).
  • · Filing signed by Anthony Austreng, Chief Compliance Officer; filer is a Georgia-based LLC (Alpharetta, GA).
  • · No period-over-period comparison is possible as only a single-quarter snapshot is provided in this filing.

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 50 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US SEC Filings Daily Market Digest

🇺🇸 More from United States

View all →